Relevant bibliographies by topics / Cancer pain Chemotherapy

Academic literature on the topic 'Cancer pain Chemotherapy'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer pain Chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer pain Chemotherapy"

1

Hancock, E. William. "Chest Pain During Cancer Chemotherapy." Hospital Practice 20, no. 7 (July 15, 1985): 93–97. http://dx.doi.org/10.1080/21548331.1985.11703097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Savage, L. "Chemotherapy-Induced Pain Puzzles Scientists." JNCI Journal of the National Cancer Institute 99, no. 14 (July 10, 2007): 1070–71. http://dx.doi.org/10.1093/jnci/djm072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Choi, Kyomin, and Jeeyoung Oh. "Peripheral Neuropathy and Pain Caused by Cancer Chemotherapy." Journal of the Korean Neurological Association 39, no. 1 (February 1, 2021): 1–9. http://dx.doi.org/10.17340/jkna.2021.1.1.

Full text
Abstract:
Peripheral neuropathy and pain are common adverse effects of chemotherapy, which incidence are rising significantly commensurate with extension of survival period in cancer patients. Chemotherapy-induced peripheral neuropathy is caused by most commonly used chemotherapeutic agents including platinum compounds, taxenes, proteasome inhibitors, thalidomide, and vinca alkaloids. Management of neuropathy and pain caused by chemotherapy is still challenging due to there is no proven therapies and preventive methods. The pain and its impact are becoming a main deterioration factor in quality of life and economic burden in our society. We review the mechanism, clinical characteristics, updated evidence of possible management of neuropathy and pain caused by traditional chemotherapeutic agents for contributing to the application of clinicians in their actual medical environment.
APA, Harvard, Vancouver, ISO, and other styles
4

Yosra, Yahyaoui, Ghorbel Achref, Charfi Lamia, Gamoudi Ahmed, Gabsi Azza, and Mezlini Amel. "Low Grade Abdominal Leiomyosarcoma with Liver Metastasis: A Second Cancer Twenty Years after Treatment for Nasopharyngeal Cancer." Clinical Oncology Research and Reports 1, no. 2 (November 16, 2020): 01–03. http://dx.doi.org/10.31579/2693-4787/015.

Full text
Abstract:
Background: leiomyosarcoma is one of the most frequent soft tissues and abdominal-pelvic sarcomas however intra-abdominal leiomyosarcoma with liver metastasis remain a very rare disease. Case presentation: A 61 year-old man presented in February 2019 a recent history of abdominal pain and weight loss. Imagery showed a 5 cm abdominal mass with multiples liver lesions. Biopsy of the liver lesions concluded to a metastases of a low grade leiomyosarcoma. Surgical resection was deemed not possible due to anatomical restrictions and the patient received 6 cycles of systemic mono-chemotherapy with epirubicin. A CT scan performed after the chemotherapy showed a stable disease using RECIST criteria. Conclusions: In case of an unresectable liver metastasis palliative chemotherapy can be offered although it is widely recognized that leiomyosarcoma show moderate sensitivity to chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Fonte, Carlos E., and Frank Cardello. "Chest Pain in a Cancer Patient on Chemotherapy." Hospital Practice 26, no. 7 (July 15, 1991): 145–46. http://dx.doi.org/10.1080/21548331.1991.11704212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Banipal, R. P. S., and M. K. Mahajan. "Methotrexate Revisited—in Recurrent Head and Neck Cancer." Palliative Care: Research and Treatment 5 (January 2011): PCRT.S6107. http://dx.doi.org/10.4137/pcrt.s6107.

Full text
Abstract:
Aims Response of single agent chemotherapy in improving quality of life in patients with recurrent head and neck cancers. Methods and material This is a study of the 18 patients with advanced cancers of head and neck, who had failed earlier attempts of radical treatment with Surgery, Radiotherapy ± chemotherapy and have residual or recurrent tumours, were treated with single agent Injection Methotrexate 50 mg/m2 weekly. Follow up visit complaints and clinical examination details were recorded. History regarding pain, speech and diet was collected for every visit. Severity of pain was divided with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 pain scales. Symptom control was done with analgesics, antiemetic and infection control. Results Weekly single agent chemotherapy with injection Methotrexate has significantly improved the quality of life of patients. 38.8% of patients have shown good response with decrease in the tumour bulk by more than 50% and other 39% of patients have stable disease on Injection Methotrexate. 22.2% patients have shown disease progression on single agent chemotherapy. Overall 83.3% patients have shown improvement in Quality of life in terms of symptomatic control. After 6 weekly treatments with injection methotrexate 63% patients were pain free with 16% patients reported decrease in pain. 87.5% of patients have shown improvement in speech and diet. Improvement in symptoms has shown decrease in depression in cancer patients. Grade 3 toxicity observed was Neutropenia (11.1%), anaemia (11.1%) and Mucositis (16.6%) which was managed adequately. Median survival with good quality of life is 5.4 months. Conclusions Single agent methotrexate chemotherapy on an out-patient basis can provide good quality of life. Decrease in pain along with improvement in speech and diet has shown decrease in incidence of depression and overall positive impact on psychosocial status. Few cases have shown sustained regression of gross disease adding to maintained quality of life with better socio-economic compliance.
APA, Harvard, Vancouver, ISO, and other styles
7

Lin, Jaung-Geng, and Yi-Hung Chen. "The Role of Acupuncture in Cancer Supportive Care." American Journal of Chinese Medicine 40, no. 02 (January 2012): 219–29. http://dx.doi.org/10.1142/s0192415x12500176.

Full text
Abstract:
Acupuncture has many beneficial effects during cancer therapy and has proven efficacy in the management of side effects induced by chemotherapy and radiotherapy. In this review, we discussed the benefits of acupuncture on cancer patients. In cancer pain management, acupuncture is effective for head and neck pain, waist pain, abdominal and chest pain. Many studies confirm the excellent efficacy of acupuncture against symptoms of vomiting and nausea, including those induced by chemotherapy and radiotherapy. Head and neck cancer patients receiving radiotherapy may develop xerostomia, which may be relieved by acupuncture. Acupuncture may also cause sedative and hypnotic effects in cancer patients for treating nervousness and insomnia.
APA, Harvard, Vancouver, ISO, and other styles
8

Coffeen, Ulises, Marco Antonio Sotomayor-Sobrino, Ariadna Jiménez-González, Luis Gerardo Balcazar-Ochoa, Pamela Hernández-Delgado, Ana Fresán, Ricardo Plancarte-Sánchez, Daniela Arias-Muñoz, and Abraham Ochoa-Aguilar. "Chemotherapy-induced neuropathic pain characteristics in Mexico’s National Cancer Center pain clinic." Journal of Pain Research Volume 12 (May 2019): 1331–39. http://dx.doi.org/10.2147/jpr.s186107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ramaekers, Ryan C., Jon Olsen, Angela Mae Obermiller, Melhem Salim Jabbour, Mark Tharnish, Megan Schriner, Rita Hays, et al. "Efficacy and safety of half-dose pegfilgrastim in cancer patients receiving cytotoxic chemotherapy." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9110. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9110.

Full text
Abstract:
9110 Background: Pegfilgrastim reduces neutropenia risk in patients (pts) on cytotoxic chemotherapy. A single 6 mg dose per chemotherapy cycle commonly causes bone pain and leukocytosis. While half-dose pegfilgrastim has been shown to be safe and effective in breast cancer pts, there is no data on half-dose pegfilgrastim in general oncology pts. Methods: We evaluated the efficacy and safety of half-dose pegfilgrastim in general oncology pts on cytotoxic chemotherapy at St Francis Cancer Center. Pts who received at least one dose of 6 mg pegfilgrastim and developed NCI-CTCAE grade 2 or more bone pain and/or leukocytosis (WBC>10,000/ml) were given 3 mg dose pegfilgrastim on their following chemotherapy cycles. Pt demographics, type/number of chemotherapy regimens, efficacy, side effects and complications were evaluated. McNemar’s test, logistic regression analysis and ANOVA were used for statistical analysis. Results: Twenty-six pts (3 males, 23 females, all Caucasian) with median age 55 (range 34-86) received a total of eighty-three 3 mg doses of pegfilgrastim. Cancers treated were breast (N=16), colorectal (N=7), head and neck (N=1), non-Hodgkin lymphoma (N=1) and non-small cell lung cancer (N=1). Chemotherapy received was anthracycline (N=9), taxane (N=7), 5-FU/oxaliplatin (N=7), 5-FU/cisplatin (N=1), gemcitabine/oxaliplatin (N=1), pemetrexed/carboplatin (N=1). No neutropenia or chemotherapy dose modifications occurred on half-dose pegfilgrastim. In the 26 pts we report, bone pain occurred in 23 pts at 6 mg and 14 pts at 3 mg dose. Leukocytosis occurred in 23 pts at 6 mg and only 2 pts at 3 mg dose (McNemar’s test, P<0.01). While older age and full-dose pegfilgrastim were predictive of bone pain, more than one line of chemotherapy and half-dose pegfilgrastim were predictive of lack of leukocytosis (logistic regression analysis/ANOVA, P<0.01). Conclusions: Half-dose pegfilgrastim in general oncology pts receiving cytotoxic chemotherapy seems to be safe and effective with less bone pain and leukocytosis without resultant neutropenia or need for chemo modification. Larger prospective studies of half-dose pegfilgrastim in this setting are needed to further understand the feasibility of this approach.
APA, Harvard, Vancouver, ISO, and other styles
10

Venkata Durga, Vinoothna Thelkar, Parineethi Karanam, Jyoshna Pisini Vyshnavy, Sadasiva Rao Galaba, and Srikanth Boga. "Pain Assessment in Breast Cancer Patients." Journal of Pharmaceutical Quality Assurance and Quality Control 4, no. 1 (June 29, 2022): 27–34. http://dx.doi.org/10.46610/jqaqc.2022.v04i01.006.

Full text
Abstract:
Introduction: Breast cancer is the most prevalent cancer among women population. Pain during and after chemotherapy is of various types and has no background information on the mechanism and treatment. Aim: To analyse pain after chemotherapy in breast cancer patients. Materials and Methods: It was a Prospective Observational Cohort of 6 month time period at Omega Hospitals, Guntur with 76 patients. Data was collected by direct interaction either with the patient or the patient representative or by studying patient’s profile through questionnaire. Statistical Analysis: All the collected data was entered into Excel sheet (Microsoft Excel 2016 MSO (16.0.13328.20262) 32-bit: Windows 11 version). The collected data was transported to SPSS (version – 28) for analysis. Results: The intermittent pain was seen in most of the patients (40.8%) along with Continuous Pain (14.5%) & Predominantly Neuropathic Pain (3.9%). Conclusion: Inspite of robustic research on the characteristics of pain, patients complain of pain in other locations too. Also, researches should throw light on management, prevention and identification of pain by various techniques like radiation or surgery. We can certainly hope that by considering diagnosis, management, prevention we can improve clinical patient outcome with less adverse drug reactions.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer pain Chemotherapy"

1

Jeon, Sangchoon. "Factors associated with time to resolution of pain and fatigue among cancer patients undergoing chemotherapy in a cognitive behavioral intervention group." Diss., Connect to online resource - MSU authorized users, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hellerstedt-Börjesson, Susanne. "Smärta vid adjuvant cytostatikabehandling : Uppfattningar och inverkan på dagligt liv hoskvinnor diagnostiserade med bröstcancer." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-156063.

Full text
Abstract:
Featured adjuvant chemotherapy treatment in women with breast cancer can lead to pain. The aim of this study was to explore, the variety of perceptions and impact of adjuvantchemotherapy-induced pain in daily life, of some women newly diagnosed with breast cancer.Inclusion criteria were participating in an ongoing stress management projectand chemotherapy of (anthracycline/taxan) in doses of 75mg² or more. Exclusioncriteria were inability to understand and communicate in Swedish and mentalillness. After ethical approval of the sub study in September 2010, women wereconsecutively included through oral and written request. Phenomenologicalapproach was used in the eight interviews and data analysis. The resultconsisted of five categories of description, the obvious pain, themanageable pain, the lonely pain, the unimaginable pain andultimately the crippling pain. The existence was open when the pain feltdescribable and manageable, while it was concluded when the pain seemedinexplicable and life drastically changed. The study showed a significantpainful impact of chemotherapy. The woman had difficulties to refer to theinformation given by the medical services, when the pain went beyond previousexperiences. There was a tendency that the woman waited before she contactedthe medical services, this waiting made room for difficult thoughts andfeelings. A question for further research is how the staff can capture andbetter help the women who experience severe pain.
Dagens adjuvanta cytostatikabehandlingav kvinnor med bröstcancer kan leda till smärta. Denna studies syfte var att undersöka olikauppfattningar om inverkan av smärta, utlöst av adjuvant cytostatikabehandling,på dagligt liv hos några kvinnor som nyligen diagnostiserats med bröstcancer.Inklusionskriterier var deltagande i ett pågående stresshanteringsprojekt ochcytostatikabehandling i doser om 75mg² eller mer av antracyklin och/ellertaxan. Exklusionskriterier var oförmåga att förstå och kommunicera på svenska ochpsykisk sjukdom. Efter etiskt godkännande av delstudien i september 2010 inkluderades kvinnorna konsekutivt genommuntlig och skriftlig förfrågan. Fenomenologisk ansats användes i de åttaintervjuerna och i resultatbearbetningen. Resultatet kom att utgöras av fembeskrivningskategorier: den förklarliga smärtan, den övervinneliga smärtan, denensamma smärtan, den ofattbara smärtan och sist den förlamande smärtan.Tillvaron var öppen då smärtankändes förklarbar och därmed hanterbar, medan den slöts när smärtan kändesoförklarlig och kvinnornas liv förändrades drastiskt. Studien visar på en betydande smärtinverkan vid cytostatikabehandling. Kvinnornafick svårt att referera till den av sjukvården givna informationen, när smärtangick utanför tidigare beskrivning och smärtupplevelser. Det fanns en tendensatt kvinnan avvaktade innan hon kontaktade sjukvården och i denna väntanuppstod svåra tankar och känslor. En fråga för vidare forskning är hurpersonalen kan fånga upp och bättre hjälpa de kvinnor som får svåra smärtor.
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, Shu-Fen, and 林淑棻. "Pain,Depression and Quality of Sleep in Lung Cancer Patients during Chemotherapy." Thesis, 2008. http://ndltd.ncl.edu.tw/handle/88063119741884307947.

Full text
Abstract:
碩士
長庚大學
護理學研究所
96
The purpose of this study was to explore the longitudinal change in and relationship among pain, depression, and sleep quality in lung cancer patients treated with chemotherapy. A total of 116 patients with lung cancer were recruited. Patients completed Brief Pain Inventory (BPI, Hospital Anxiety and Depression Scale(HADS), and Pittsburgh Sleep Quality Index (PSQI) at pre-chemotherapy and at the 15th day of every chemotherapy cycle for 6 cycles. Data were analyzed using descriptive statistic, Pearson correlation and mixed effect models. The study results showed: (1) the average pain levels were mild through out six chemotherapy cycles with pre-chemotherapy level being the highest. (2) Most of the patients were not depressed through out six chemotherapy cycles. Depressive scores were high at pre-chemotherapy but gradually decreased through out the chemotherapy cycles. Depressive scores at pre-chemotherapy and the 1st cycles were significantly higher than other cycles. (3) During days when chemotherapy was given, sleep quality were continuously worsen from the 2nd to the 5th cycles. During days when chemotherapy was not given (rest period), sleep quality was poor at the 1st cycle and improved at the 2nd and 3rd cycle, then fluctuated at the 4th and 6th cycles; the sleep quality at pre-chemotherapy and the 1st cycle was significantly poorer than that of other cycles. (4) Significant correlations were found between average pain level and sleep quality at the 4th and 6th cycles and between depression and sleep quality at all cycles. (5) Income had significant effect on sleep quality; patients with low income had poorer sleep quality. (6) During days when chemotherapy was given, there was a significant interaction effect on sleep quality between type of chemotherapy agent and time. The sleep quality for patients treated with traditional chemotherapy agents was deteriorate over time; but for patients treated with new drugs (e.g., target therapy), the sleep quality tended to improve over time.
APA, Harvard, Vancouver, ISO, and other styles
4

(8766597), Parul Verma. "Towards Understanding Neuropathy from Cancer Chemotherapy and Pathophysiology of Pain Sensation: An Engineering Approach." Thesis, 2020.

Find full text
Abstract:
This thesis addresses chemotherapy-induced peripheral neuropathy (CIPN)- a form of pain sensation and a prevalent dose-limiting side-effect of several chemotherapy agents such as vincristine, paclitaxel, and oxaliplatin. These agents are used for treating various cancers such as leukemia, brain tumor, lung cancer. Peripheral neuropathy is a numbing, tingling, and burning sensation felt in the palms and feet, which occurs due to damage to neurons (nerve cells). Prolonged CIPN can impact the quality of life of cancer patients. Occasionally, severe CIPN can result in termination of chemotherapy treatment altogether. Currently, there are no established strategies for treating CIPN due to a lack of understanding of its mechanisms. Moreover, different patients react differently to the same treatment; a subgroup of patient population may never experience CIPN, while another may experience severe CIPN for the same dose. In addition, there are no established strategies for predicting CIPN either. This thesis addresses both prediction and mechanisms of CIPN.

The following paragraphs reflect the organization of this thesis. Each paragraph introduces a research problem, the approaches taken to investigate it, and states the key results.

First, a metabolomics-based approach was used to investigate CIPN prediction. Blood samples of pediatric leukemic cancer patients who underwent treatment with a chemotherapy agent - vincristine were provided. These blood samples were analyzed at different treatment time points using mass spectrometry to obtain the metabolite profiles. Machine learning was then employed to identify specific metabolites that can predict overall susceptibility to peripheral neuropathy in those patients at specific treatment time points. Subsequently, selected metabolites were used to train machine learning models to predict neuropathy susceptibility. Finally, the models were deployed into an open-source interactive tool- VIPNp- that can be used by researchers to predict CIPN in new pediatric leukemic cancer patients.

Second, the focus was shifted to the pathophysiology of pain and the pain-sensing neuron; specifically: (i) investigating pain sensation mutations and the dynamics of the pain-sensing neuron, and (ii) exploring chemotherapy-induced peripheral neuropathy mechanisms.

While pain is a common experience, genetic mutations in individuals can alter their experience of pain, if any at all (certain mutations yield individuals insensitive to pain). Despite its ubiquity, we do not have a complete understanding of the onset and/or mechanisms of pain sensation. Pain sensation can be broadly classified into three types: (i) nociceptive, (ii) neuropathic, and (iii) inflammatory. Nociceptive pain arises due to a noxious external stimulus (e.g., upon touching a hot object). Neuropathic pain (which is felt as a side-effect of the aforementioned chemotherapy agents) is the numbing and tingling sensation due to nerve damage. Inflammatory pain occurs due to damage to internal tissues. Pain in any form can be characterized in terms of electrical signaling by the pain-sensing neuron. Signal transmission regarding pain occurs through generation of an electrical signal called the action potential- a peak in neuron membrane potential. Excessive firing of action potentials by a pain-sensing neuron indicates pain of a specific form and intensity. In order to investigate this electrical signaling, a mathematical modeling approach was employed. The neuron membrane was assumed to be an electrical circuit and the potential across the membrane was modeled in terms of the sodium and potassium ions flowing across it via voltage-gated sodium and potassium channels, respectively. Generation of a single action potential followed by a resting state corresponds to a normal state, whereas periodic firing of action potentials (an oscillatory state) corresponds to pain of some form and intensity in vitro. Therefore, an investigation into the switch from a resting state to an oscillatory state was proposed. A bifurcation theory approach (generally useful in exploring changes in qualitative behavior of a model) was used to explore possible bifurcations to explain this switch. Firstly, genetic mutations that can shift the pain sensation threshold in the pain-sensing neuron were explored. The detected bifurcation points were found to be sensitive to specific sodium channels’ model parameters, implying sodium channels’ sensitivity towards the pain sensation threshold. This was corroborated by experimental evidence in existing literature. Secondly, a theoretical analysis was performed to explore all possible bifurcations that can explain the dynamics of this pain-sensing neuron model. The mathematical modeling simulations revealed a mixture of small amplitude and large amplitude membrane potential oscillations (mixed-mode oscillations) for specific parameter values. The onset and disappearance of the oscillations were investigated. Model simulations further demonstrated that the mixed-mode oscillations solutions belonged to Farey sequences. Furthermore, regions of bistability- where stable steady state and periodic solutions coexisted- were explored. Additionally, chaotic behavior was observed for specific model parameters.

Finally, this thesis investigated the role of voltage-gated ion channels in inducing CIPN using the same mathematical model. Repetitive firing of action potentials in the absence of any external stimulus was used as an indicator of peripheral neuropathy. Bifurcation analysis revealed that specific sodium and potassium conductances can induce repetitive firing without any external stimulus. The findings were supplemented by recording the firing rate of a sensory neuron culture. Next, a chemotherapy agent - paclitaxel, was introduced in the model to investigate its potential effects on the firing behavior. It was seen that a medium dose of paclitaxel increased repetitive firing. This was supported by the firing rate recordings of the sensory neuron culture.

In summary, this thesis presents a prediction strategy for CIPN. Moreover, it presents a bifurcation theory-based framework that can be used to investigate pain sensation, in particular, genetic mutations related to pain sensation and chemotherapy-induced peripheral neuropathy. This framework can be used to find potential voltage-gated ion channels that can be targeted to control the pain sensation threshold in individuals, and can be extended to investigate various degeneracies in CIPN mechanisms to find therapeutic cures for it.
APA, Harvard, Vancouver, ISO, and other styles
5

Tsai, Hsiu-Fen, and 蔡秀芬. "Exploring the Effects of Music Therapy on Pain, Fatigue, Anxiety, and Depression in Cancer Patients Undergoing Chemotherapy." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/us2w4s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Robarge, Jason Dennis. "Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons." Thesis, 2014. http://hdl.handle.net/1805/6056.

Full text
Abstract:
Indiana University-Purdue University Indianapolis (IUPUI)
Aromatase inhibitors (AIs) are the current standard of care for the treatment of hormone receptor positive breast cancer in postmenopausal women. Nearly one-half of patients receiving AI therapy develop musculoskeletal toxicity that is characterized by joint and/or muscle pain and approximately one-fourth of patients discontinue their therapy as a result of musculoskeletal pain. Since there are no effective strategies for prevention or treatment, insight into the mechanisms of AI-induced pain is critical to improve treatment. However, there are few studies of AI effects in animal models of nociception. To determine whether AIs produce hypersensitivity in animal models of pain, I examined the effects of AI administration on mechanical, thermal, and chemical sensitivity in rats. The results demonstrate that (1) repeated injection of 5 mg/kg letrozole in male rats produces mechanical, but not thermal, hypersensitivity that extinguishes when drug dosing is stopped; (2) administering a single dose of 1 or 5 mg/kg letrozole in ovariectomized (OVX) rats also induces mechanical hypersensitivity, without altering thermal sensitivity and (3) a single dose of 5 mg/kg letrozole or daily dosing of letrozole or exemestane in male rats augments flinching behavior induced by intraplantar ATP injection. To determine whether the effects of AIs on nociceptive behaviors are mediated by activation or sensitization of peptidergic sensory neurons, I determined whether letrozole exposure alters release of calcitonin gene-related peptide (CGRP) from isolated rat sensory neurons and from sensory nerve endings in rat spinal cord slices. No changes in basal, capsaicin-evoked or high extracellular potassium-evoked CGRP release were observed in sensory neuronal cultures acutely or chronically exposed to letrozole. Furthermore, letrozole exposure did not alter the ability of ATP to augment CGRP release from sensory neurons in culture. Finally, chronic letrozole treatment did not augment neuropeptide release from spinal cord slices. Taken together, these results do not support altered release of this neuropeptide into the spinal cord as mediator of letrozole-induced mechanical hypersensitivity and suggest the involvement of other mechanisms. Results from this dissertation provide a new experimental model for AI-induced hypersensitivity that could be beneficial in delineating mechanisms mediating pain during AI therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Ling-Chun, and 盧怜君. "The Relationships of Chemotherapy Induced Peripheral Neuropathic Pain, Activities of Daily Lives, Mood, and Quality of Life in Patient with Colorectal Cancers." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/43271838190560887976.

Full text
Abstract:
碩士
國立臺北護理健康大學
護理研究所
100
The purpose of this study was to investigate the relationships of chemotherarpy induced neuropathic pain, activies of daily lives, mood and quality of life among patients with colorectal cancer in Taiwan. A convenience sample was used in this cross-sectional study. The data was collected by self-administrated questionnaires. The instruments included Neuropathic Pain Symptom Inventory (NPSI)、Screening of Activity Limitation and Safety Aweareness Scale (SALSA scale）、Profile of Mood States short form (POMS SF）and Functional Assessment Cancer Therapy-Colorectal instruments version 4 (FACT-C version 4) as well as self-constructed items. A total of 106 questionnaires were distributed. The results revealed majority of the participants were male (53.8%) and married (77.4%). The average age was 56.92(SD=11.35). The level of education and occupation in most participants were senior high school (29.2%) and housekeeper (20.8%). The stage of cancer in most participants was stage III (60.4%) and IV (34.0%). There was history of chronic disease in the majority of the participants (63.2%) as well as history of post radical resection following by oxaliplatin/ 5-Fu-based chemotherapy (FOLFOX) (95.3%). On the incidence of chemotherapy induced neuropathic pain, majority of the participants is slight (93.4%). The severity of chemotherapy induced neuropathic pain from high to low was paraesthesia, intermittently neuropathic pain, induced neuropathic pain, and spontaneously neuropathic pain, subsequently. On the domain of activities of daily lives, minority of the participants is slight restriction (11.3%). The restrictive severity of activities of daily lives from high to low was self-care, work of hand, dexterity of hands and mobility of feet, subsequently. The score of each domain in mood from high to low was vigor-activity, confusion-bewilder, fatigue-inevtia, tension-anxiety, depression- dejection, and anger-hostility, subsequently. The results indicated that there were a low positive correlation between paraesthesia and dexterity of hands (r＝.196, p<.05), a medium positive correlation between neuropathic pain and mood (r＝.492, p<.001), a medium negative correlation between spontaneously neuropathic pain and quality of life (r＝-.254, p<.01). In additional, a medium positive correlation between activities of daily lives and mood (r＝.388, p<.01), a medium negative correlation between activities of daily lives and quality of life (r＝-.328, p<.01) and a high negative correlation between mood and quality of life were reported (r＝-.615, p<.001). Results from the hierarchical multiple regression analysis detected that stage, accumulative dose of chemotherapy, spontaneously neuropathic pain, and activies of daily lives were determinants in quality of life before mood was included. They can explained 45.2% of the variance on quality of life. Furthermore, the mediating effects of perceived mood on quality of life was analyzed by ordinary least square multiple regression analysis. The result showed 42.51% variance of spontaneously neuropathic pain on quality of life and 43.17% variance of activies of daily lives on quality of life could explained by perceived mood. The result from the current study may provide new insight into status and relationships of chemotherapy induced neuropathic pain, activies of daily lives, mood and quality of life among the patients with colorectal cancer. Strategies which aim to improve the quality of life among patients with colorectal cancer may be developed through the enhancement of nursing evaluation of chemotherapy induced neuropathic pain, activities of daily lives and mood, as well as strengthening management of care guideline.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cancer pain Chemotherapy"

1

Karen, Forbes, ed. Opioids in cancer pain. Oxford: Oxford University Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Society, Canadian Cancer, ed. The pain manual: Principles and issues in cancer pain management. Montréal: Pegasus Healthcare, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stannard, Catherine F. Opioids in non-cancer pain. Oxford: Oxford University Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Logan, Marion. Continuous subcutaneous infusion of narcotics: Patient care and family support ; guide for CSCI nurses. Ottawa: University of Ottawa Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

P, Squires Bruce, Canadian Cancer Society, and Canadian Association of Nurses in Oncology., eds. The pain manual: Principles and issues in cancer pain management. Montreal: Pegasus Healthcare International, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1928-, Hill C. Stratton, and Fields William S. 1913-, eds. Drug treatment of cancer pain in a drug-oriented society. New York: Raven Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cardiff), Developing alternative models of care for pain management and cancer chemotherapy in Wales (1994. Developing alternative models of care for pain management and cancer chemotherapy in Wales: Proceedings of a seminar. Cardiff: Welsh Office, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

A, Lack Sylvia, ed. Therapeutics in terminal cancer. Edinburgh: Churchill Livingstone, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

A, Lack Sylvia, ed. Therapeutics in terminal cancer. 2nd ed. Edinburgh: Churchill Livingstone, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States. Congress. Senate. A bill to establish a temporary program under which parenteral diacetylmorphine will be made available through qualified pharmacies for the relief of intractable pain due to cancer, and for other purposes. [Washington, D.C.?]: [United States Government Printing Office], 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer pain Chemotherapy"

1

Monfardini, S., and A. Scanni. "Chemotherapy and Radiotherapy for Cancer Pain." In Cancer Pain, 89–96. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-010-9139-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Resnick, Seth. "Cancer Pain Management, Chemotherapy." In Encyclopedia of Pain, 364–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-28753-4_527.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gritsenko, Karina, and Michael Lubrano. "Chemotherapy." In Essentials of Interventional Cancer Pain Management, 19–27. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-99684-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abrams, Ross A., and Richard M. Hansen. "Radiotherapy, Chemotherapy and Hormonal Therapy in the Management of Cancer Pain: Putting Patient, Prognosis, and Oncologic Options in Perspective." In Cancer Pain, 49–66. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-0875-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nersesyan, Hrachya, Jeffrey J. Mucksavage, Eljim Tesoro, and Konstantin V. Slavin. "Pain Management in Cancer Patients." In Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures, 437–52. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9704-0_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jamar, Susan Christensen. "Fatigue in Women Receiving Chemotherapy for Ovarian Cancer." In Management of Pain, Fatigue and Nausea, 224–28. London: Macmillan Education UK, 1989. http://dx.doi.org/10.1007/978-1-349-13397-0_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vermorken, Jan B. "Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer." In Critical Issues in Head and Neck Oncology, 155–79. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_11.

Full text
Abstract:
AbstractThe treatment of locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) is reviewed, highlighting the milestones in systemic therapy in that setting, with focus on the role of induction chemotherapy (ICT). The road to what is now considered the standard ICT regimen, i.e. the TPF (docetaxel/cisplatin/5-FU) regimen is described, and the differences between the European and the American TPF are discussed. The article describes the respective roles of ICT for larynx preservation, for treatment intensification, its role in patients with borderline resectable or unresectable oral cavity cancer, its role as a selection tool for radiotherapy dose de-escalation in patients with oropharyngeal squamous cell cancer (OPSCC) and its potential future role in strategies aiming at synchronous oligometastatic disease.ICT has an established role for organ preservation in advanced laryngeal and hypopharyngeal cancer and the TPF regimen has been validated in that setting. This approach is presently being compared in a randomized controlled trial to concurrent chemoradiotherapy (CCRT), which in many parts of the world is considered the standard organ preservation procedure. There remains uncertainty about the benefit of the sequential approach of ICT followed by CCRT, despite the fact that ICT significantly reduces the occurrence of distant metastases. It is advised that future studies should include patients who have the highest risk to develop distant metastases, in particular patients with low neck nodes and matted nodes. Moreover, further studies in patients with HPV-associated OPSCC at risk for distant failure (T4 or N3 disease) should be considered for that also. These approaches still need to be confirmed in adequately sized randomized controlled trials. Outside clinical trials, the utility of ICT is restricted to uniquely pragmatic clinical scenarios, such as unavoidable delay in radiation or in the situation that RT is not tolerated or feasible. This can happen when there is severe pain from advanced disease or there is impending airway compromise or neurologic dysfunction that necessitates rapid initiation of treatment. In all those circumstances whether within the context of trials or outside trials, it is imperative that the present backbone of ICT, the TPF regimen, is being administered by experienced oncologists, familiar with the necessary protocols and supportive care requirements to ensure patient safety and maximize adherence throughout the treatment.Future areas of research are the role of ICT in strategies whereby ICT is combined with upfront metastases-directed treatments and the usefulness of targeted agents or immune checkpoint inhibitors in the induction setting. Studies in that direction have already started. Finally, the application of radiographic, proteomic and genomic biomarkers will get attention to further define prognostic groups and guide treatment selection with greater precision.
APA, Harvard, Vancouver, ISO, and other styles
8

JAVLE, MILIND, and G. VARMA. "Chemotherapy for Cancer Pain Management." In Cancer Pain, 459–64. Elsevier, 2006. http://dx.doi.org/10.1016/b978-0-7216-0261-5.50041-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Caplan, Rachel, and Kate Brizzi. "Chemotherapy-Induced Peripheral Neuropathy." In Pain, 269–76. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197542873.003.0032.

Full text
Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling sequelae of numerous chemotherapeutic agents used in the treatment of cancers. When it occurs during treatment, it may lead to early cessation of chemotherapy and thus increased risk of cancer mortality. As a chronic illness, it can have serious effects on independence and quality of life for years after chemotherapy has ended. While the incidence of acute neuropathic pain during treatment can approach 90%, more than half of patients may experience prolonged neuropathy symptoms following cessation of therapy. Prior to attributing neuropathic pain to chemotherapy, clinicians should be vigilant to rule out other common causes. Pharmacologic and nonpharmacologic modalities exist for both the prevention and treatment of CIPN, and judicious monitoring must be conducted.
APA, Harvard, Vancouver, ISO, and other styles
10

Murtagh, Fliss E., and Irene J. Higginson. "Cancer neuropathic pain." In Neuropathic Pain, 75–83. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199563678.003.0009.

Full text
Abstract:
Around a third of cancer pains may have a neuropathic component and mixed pathology is more usual than pure neuropathic pain Compression and infiltration of nerves by tumour are the most common causes Treatment-induced damage (chemotherapy-induced neuropathy, radiation plexitis, surgical trauma) and paraneoplastic syndromes are less common causes...
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer pain Chemotherapy"

1

IPEK, Fulya, Vesile Yıldız Kabak, Songül Atasavun Uysal, and Tulin Duger. "AB0916 INVESTIGATION OF PAIN AND DEPRESSION IN CANCER OUTPATIENTS RECEIVING CHEMOTHERAPY." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rosenzweig, Margaret Quinn, and Susan Wesmiller. "Abstract C11: Racial differential in pain and nausea during breast cancer chemotherapy." In Abstracts: Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 13-16, 2015; Atlanta, Georgia. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7755.disp15-c11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685313.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated with 3 cycles of neoadjuvant chemotherapy and then taken up for interval debulking surgery (IDS) who had static or partial or complete response to chemotherapy. The remaining chemotherapy is delivered after the surgery. Patient who had limited disease had primary debulking surgery and then adjuvant chemotherapy according to institute protocol. Outcomes in terms of disease free and overall survival were analysed. Results: This retrospective analysis included 59 patients with limited disease who had primary debulking surgery and 283 patients with advanced disease who received neoadjuvant chemotherapy. The median age was 50 years and majority are in the 50-59 years age group. Age more than 60 years represent 14.5%. Postmenopausal women were55.3 % and premenopausal women were 44.7 %. Multiparity is higher 70.2% than the uniparity 16.4% ornulliparity 11.7%. Abdomen distension 42% and pain 25 % are the most common symptoms. Advanced stage was the most common presentation 71% with stage III-56.1% and stage IV-14.9%. Among the neoadjuvant chemotherapy group 126/283(44.5%) had optimal cytoreduction, 44/283 (15.5%) had suboptimal cytoreduction and 113/283 (40%) not suitable for IDS. The 5 year disease free and overall survival was 30.8% and 41.5% in the NACT group with advanced disease and 58.5% and 75.8% in the primary cytoreduction group who had limited diseaserespectively. The 5 years overall survival among the IDS group with optimal cytoreduction was 57.1% and 11.7% for the suboptimal cytoreduction group. The 5 years survival was not affected by the number of neoadjuvant chemotherapy cycles delivered before surgery in the IDS group. Patient who received paclitaxol + carboplatin as first line chemotherapy had better survival than carboplatin alone or cyclophosphamide + cisplatin. Conclusion: NACT as an alternative option to primary debulking surgery in operable EOC is still debatable. But for patient with high disease burden where optimal cytoreduction is not possible NACT strategy is a valid option. Recent randomised controlled trials from Europe had shown the noninferiority of neoadjuvant chemotherapy followed by IDS when compared to the primary debulking surgery in operable advanced EOC.
APA, Harvard, Vancouver, ISO, and other styles
4

Nascimento, Ranier Colbek, and Sabrina Ribas Freitas. "A 29-YEAR-OLD PREGNANT WOMAN WITH METASTATIC BREAST CANCER: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2107.

Full text
Abstract:
Pregnancy-associated breast cancer (PABC) is defined as a breast cancer diagnosed during pregnancy, lactation, or in the first postpartum year. PABC is a rare complication that occurs in approximately 0.01% to 0.03% of all pregnancies. The difficulty in diagnosis worsens the prognosis. D.G., 29-year-old, female, noted a mass in her right breast in June 2020. One month later with 13+4 weeks’ gestation, she presented to the obstetrics emergency with recurrent episodes of lower back pain. She was released home with pain relief and was instructed to realize a mammography due to the presence of a 4-cm mass on physical examination of the right breast. Patient returned 12 days later with severe low back pain, a BIRADS 4C mammography, and multiple liver lesions in total abdomen ultrasound. Core-needle biopsy demonstrated a stage II invasive ductal carcinoma with hormone receptors positive and human epidermal growth factor receptor 2 positive. There is involvement of the axilla and intramammary lymph nodes. Magnetic resonance imaging of the lower back and sacroiliac joint was performed and found multiple lesions suspected of metastasis in the inferior thoracic vertebrae, lumbar vertebrae, sacrum, ilium, and femurs. Computed tomography (CT) of the thorax identified a 2.3×1.8 cm irregular lesion in the right breast compatible with the primary neoplasm. Chemotherapy was initiated till she was 31 weeks’ gestation. After childbirth, she reinitiates chemotherapy. Three months later, the patient has convulsive episodes. Cranial CT was done and found multiple lesions compatible with brain metastasis, so she initiated brain radiotherapy. PABC can present itself as a challenging situation with nonspecific symptoms and at an advanced stage. Therefore, it is important to have the PABC in our list of differential diagnoses in this patient.
APA, Harvard, Vancouver, ISO, and other styles
5

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685312.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated with 3 cycles ofneoadjuvant chemotherapy and then taken up for interval debulking surgery (IDS) who had static or partial or complete response to chemotherapy. The remaining chemotherapy is delivered after the surgery. Patient who had limited disease had primary debulking surgery and then adjuvant chemotherapy according to institute protocol. Outcomes in terms of disease free and overall survival were analysed. Results: This retrospective analysis included 59 patients with limited disease who had primary debulking surgeryand 283 patients with advanced disease who recievedneoadjuvant chemotherapy. The median age was 50 years and majority are in the 50-59 years age group. Age more than 60 years represent 14.5%. Postmenopausal women were 55.3% and premenopausal women were 44.7 %. Multiparity is higher 70.2% than the uniparity 16.4% ornulliparity 11.7%. Abdomen distension 42% and pain 25% are the most common symptoms. Advanced stage was the most common presentation 71% with stage III-56.1% and stage IV-14.9%. Among the neoadjuvant chemotherapy group 126/283 (44.5%) had optimal cytoreduction, 44/283 (15.5%) had suboptimal cytoreduction and 113/283 (40%) not suitable for IDS. The 5 year disease free and overall survival was 30.8% and 41.5% in the NACT group with advanced disease and 58.5% and 75.8% in the primary cytoreduction group who had limited diseaserespectively. The 5 years overall survival among the IDS group with optimal cytoreduction was 57.1% and 11.7% for the suboptimal cytoreduction group. The 5 years survival was not affected by the number ofneoadjuvant chemotherapycycles delivered before surgery in the IDS group. Patient who received paclitaxol + carboplatin as first line chemotherapy had better survival than carboplatin alone or cyclophosphamide + cisplatin. Conclusion: NACT as an alternative option to primary debulking surgery in operable EOC is still debatable. But for patient with high disease burden where optimal cytoreduction is not possible NACT strategy is a valid option. Recent randomised controlled trials from Europe had shown the noninferiority of neoadjuvant chemotherapy followed by IDS when compared to the primary debulking surgery in operable advanced EOC.
APA, Harvard, Vancouver, ISO, and other styles
6

Maxwell, CL, AS Guinigundo, L. Vanni, PK Morrow, M. Reiner, A. Shih, Z. Klippel, and E. Blanchard. "Abstract P5-09-13: The effect of bone pain–specific education vs general chemotherapy side-effect education on reported bone pain in patients (pts) with breast cancer receiving chemotherapy and pegfilgrastim." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p5-09-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gencheva, Nezabravka. "PHYSIOTHERAPY FOR COLON CANCER IN THE EARLY POSTOPERATIVE PERIOD - A CASE REPORT." In INTERNATIONAL SCIENTIFIC CONGRESS “APPLIED SPORTS SCIENCES”. Scientific Publishing House NSA Press, 2022. http://dx.doi.org/10.37393/icass2022/146.

Full text
Abstract:
АBSTRACT Introduction: The Physiotherapy (PT) is an important part of cancer treatment and could be recovery PT, maintenance PT and palliative PT. The aim of the study is to investigate the impact of early postoperative PT on the functional and mental recovery of a 57-year-old patient with colon cancer. Research methods: On the second and seventh postoperative day, we applied a Quality of Recovery-40 (QoR-15) questionnaire, Cumulated Ambulation Score (CAS) and Hospital Anxiety and Depression Scale (HADS) and а 6 min walk-test – on the third and seventh postoperative day. The special PT is used to improve the respiratory function, to alleviate the unpleasant sensations of the gastrointestinal tract, to reduce pain, to restore mobility through training in painless sitting, standing up, and walking, as well as to reduce anxiety and to overcome depressive symptoms. Results: Applied PT in the early postoperative period in severe abdominal surgery for colon cancer prevented postoperative complications. The results show a significant improvement in the studied indicators and good quality of recovery; patient’s independence in standing up, sitting, and walking; pain relief; reduced anxiety and depressive moods. Conclusion: The application of early PT is an important part of patient’s post-surgical care. It helps for optimal recovery and prepares him for the next additional therapies such as chemotherapy, radiation therapy, etc.
APA, Harvard, Vancouver, ISO, and other styles
8

Shin, Sarah, Jinhee Kim, Jin-Mu Yi, No Soo Kim, and Ok-Sun Bang. "Abstract B110: Assessments of ameliorative effect ofForsythia Fructuson chemotherapy-induced neuropathic pain and its genotoxic potential." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-b110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schwartzberg, L., M. Mo, R. Harms, and C. Vogel. "Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blebea, Nicoleta Mirela. "NUTRITIONAL THERAPY IN CLINICAL MANAGEMENT OF ONCOLOGICAL PATIENTS." In NORDSCI Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/nordsci2021/b1/v4/28.

Full text
Abstract:
Nutritional therapy helps patients with cancer to maintain their weight within normal limits, maintain tissue integrity and reduce the side effects of cancer therapies. Nutritional oncology deals with both prevention and patient support during treatment, in convalescence and in palliative situations. Cancer patients need full support from the team of health professionals (oncologists, nurses and dietitians). The following basic elements should not be missing from the cancer patient's diet: water, protein intake, animal and vegetable fats, as well as vitamins and minerals. The diet of cancer patients should be closely monitored, as body weight should be kept within normal limits, ie a body mass index (BMI) between 19 and 24 (the calculation is made by dividing the weight by the square of the height). The oncologist should therefore be aware of the adverse effects of malnutrition on patient outcomes and view nutritional support as an essential component of the clinical management, chemotherapy, radiation therapy, antiemetic treatment, and treatment for pain.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer pain Chemotherapy' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography